Human Liver Spheroids in Chemically Defined Conditions for Studies of Gene–drug, Drug–Drug and Disease–Drug Interactions
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Recent phenotypically and functionally relevant human hepatic in vitro systems combine the ability to preserve interindividual molecular differences between patients' livers in culture with the accessibility and high-throughput compatibility of in vitro assays. These features facilitate studies of specific genetic polymorphisms by using cells from donors with defined variants of interest or by selective gene knock-down experiments. Furthermore, these models constitute promising tools to evaluate drug-drug interactions as well as the effects of liver diseases on drug pharmacokinetics in co-cultures of hepatocytes and non-parenchymal cells. In the near future, we anticipate that these tools will be of high relevance for predicting the in vivo kinetics, toxicity and drug-drug interactions of drug candidates already during preclinical development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Self-citationBell, C. C., Dankers, A. C. A., Lauschke, V. M., Sison-Young, R., Jenkins, R., Rowe, C., Goldring, C. E., Park, K., Regan, S. L., Walker, T., et al. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfx289 · Cited by 327
Self-citationDowning, N. S., Shah, N. D., Aminawung, J. A., Pease, A. M., Zeitoun, J.-D., Krumholz, H. M., & Ross, J. S. (2017) · JAMA · doi:10.1001/jama.2017.5150 · Cited by 324
Multi-cell type human liver microtissues for hepatotoxicity testing
Messner, S., Agarkova, I., Moritz, W., & Kelm, J. M. (2013) · Archives of Toxicology · doi:10.1007/s00204-012-0968-2 · Cited by 319
Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro
Leite, S. B., Roosens, T., El Taghdouini, A., Mannaerts, I., Smout, A. J., Najimi, M., Sokal, E., Noor, F., Chesne, C., & van Grunsven, L. A. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.026 · Cited by 234
Bell, C. C., Lauschke, V. M., Vorrink, S. U., Palmgren, H., Duffin, R., Andersson, T. B., & Ingelman-Sundberg, M. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074369 · Cited by 201
Self-citationVorrink, S. U., Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy058 · Cited by 187
Self-citationVorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172
Self-citationMatsa, E., Burridge, P. W., Yu, K.-H., Ahrens, J. H., Termglinchan, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J. M., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.07.006 · Cited by 164
Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability
Hendriks, D. F. G., Fredriksson Puigvert, L., Messner, S., Mortiz, W., & Ingelman-Sundberg, M. (2016) · Scientific Reports · doi:10.1038/srep35434 · Cited by 156
Self-citationDevelopment of an in vitro human liver system for interrogating nonalcoholic steatohepatitis
Feaver, R. E., Cole, B. K., Lawson, M. J., Hoang, S. A., Marukian, S., Blackman, B. R., Figler, R. A., Sanyal, A. J., Wamhoff, B. R., & Dash, A. (2016) · JCI Insight · doi:10.1172/jci.insight.90954 · Cited by 153
Lauschke, V. M., Vorrink, S. U., Moro, S. M. L., Rezayee, F., Nordling, Å., Hendriks, D. F. G., Bell, C. C., Sison‐Young, R., Park, B. K., Goldring, C. E., et al. (2016) · Hepatology · doi:10.1002/hep.28780 · Cited by 121
Self-citationEngineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
Cited by
Lauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Self-citationZhou, Y., Shen, J. X., & Lauschke, V. M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01093 · Cited by 85
Self-citation3D human liver spheroids for translational pharmacology and toxicology
Ingelman‐Sundberg, M., & Lauschke, V. M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13587 · Cited by 62
Self-citationSuurmond, C. E., Lasli, S., van den Dolder, F. W., Ung, A., Kim, H., Bandaru, P., Lee, K., Cho, H., Ahadian, S., Ashammakhi, N., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201901379 · Cited by 61
Metadata
- Authors
- Ingelman-Sundberg, M., & Lauschke, V. M.
- Venue
- Pharmacogenomics
- Publisher
- Informa UK Limited
- Published
- 2018-07-25
- Volume
- 19
- Issue
- 14
- Pages
- 1133-1138
- ISSN
- 1462-2416 (ISSN-L)
- 1744-8042
- OpenAlex
- W2884012784
- Cited by
- 14
- References
- 15
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.